OakChart

Janux Therapeutics Inc

JANXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

12.39+0.35 (2.91%)
2026-11-12 04:15 CET
Market cap
758.06 USD m
Revenue, TTM
23.29 USD m
Net income, TTM
-99.85 USD m
Free cash flow, TTM
-54.16 USD m
EPS diluted, TTM
-1.59
P/E
-
Compare

Price

JANX against its 20, 50 and 200-day averages
2050200beatmiss
12.0014.0016.0018.0020.003.3M6.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26JANXclose 12.3920-day 16.5050-day 17.13200-day 15.3812.3952w low

64.9% under the 52-week high of 35.34 on 26 Nov 2025. 52-week low 11.59 on 10 Nov 2026. Last 15 sessions, 60.7% high to low

Volume 1.28× normal · the line is the 50-bar volume average

Profile

JANX
52-week range, 3% of the way up
11.5935.34

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

IndexRUT
Employees109
IPOJun 11, 2021
Beta2.44
ATR, 14d1.26
Rel volume1.28
Short float9.21%
Insider own5.41%
Inst own98.35%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap758.06M
Enterprise Value-167.28M
Income-99.85M
Sales23.29M
Book/sh14.90
Cash/sh15.46
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees109
IPOJun 11, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S32.55
P/B0.83
P/C0.80
P/FCF-
EV/EBITDA-
EV/Sales-7.18
Quick Ratio17.69
Current Ratio17.69
Debt/Eq0.02
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.59
EPS next Y-2.57
EPS next Q-0.53
EPS this Y9.99%
EPS next Y-55.72%
EPS next 5Y-19.78%
EPS past 3/5Y-6.44% -62.26%
Sales past 3/5Y5.11% -
EPS Y/Y TTM4.85%
Sales Y/Y TTM132.89%
EPS Q/Q12.78%
Sales Q/Q-7.11%
EarningsNov 05 AMC
EPS/Sales Surpr.28.19% 15.69%

Ownership

Insider Own5.41%
Insider Trans-0.18%
Inst Own98.35%
Inst Trans1.98%
ROA-9.94%
ROE-10.58%
ROIC-10.74%
Gross Margin92.02%
Oper. Margin-599.26%
Profit Margin-428.74%
SMA20-24.92%
SMA50-27.69%
SMA200-19.45%
Trades-

Technical

Shs Outstand61.17M
Shs Float57.87M
Short Float9.21%
Short Ratio5.74
Short Interest5.33M
52W High35.34 -64.94%
52W Low11.59 6.95%
Volatility17.08% 7.52%
ATR (14)1.26
RSI (14)31.69
Beta2.44
Rel Volume1.28
Avg Volume928.80K
Volume1,189,547

Performance

Perf Week-31.85%
Perf Month-27.88%
Perf Quarter-22.56%
Perf Half Y-15.20%
Perf YTD-10.22%
Perf Year-57.08%
Perf 3Y105.13%
Perf 5Y-50.20%
Perf 10Y-
Recom1.47
Target Price31.31
Prev Close12.04
Price12.39
Change %2.91%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Aug 24, 2026UpgradeWWolfe ResearchPeer Perform → Outperform$23+85.6%
Apr 20, 2026DowngradeBBarclaysOverweight → Underweight$14+13.0%
Apr 15, 2026DowngradeUUBSBuy → Neutral$15+21.1%
Nov 18, 2025InitiatedWWolfe ResearchPeer Perform
Sep 17, 2025InitiatedBBarclaysOverweight$47+279.3%
Sep 10, 2025InitiatedTTruistBuy$100+707.1%
Sep 10, 2025InitiatedSStifelBuy$45+263.2%
Sep 04, 2025InitiatedGGuggenheimBuy$72+481.1%
Aug 19, 2025InitiatedPPiper SandlerOverweight$42+239.0%
Jul 11, 2025InitiatedRRaymond JamesOutperform$65+424.6%

Peers

Mkt cap
TickerCompanyMkt cap
VIRVir Biotechnology Inc2.25B
CTMXCytomX Therapeutics Inc464.35M
XNCRXencor Inc3.00B
IMCRImmunocore Holdings plc ADR1.63B
XLOXilio Therapeutics Inc55.74M
TLXTelix Pharmaceuticals Ltd ADR3.31B
ZYMEZymeworks BC Inc2.02B
CADLCandel Therapeutics Inc705.50M
MGNXMacrogenics Inc147.78M
AMGNAMGEN Inc253.21B

Insider trading

latest 14 of 23
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Campbell David AlanPresident and CEOJul 08 '26Option Exercise4.217,00029,470388,582Jul 10 08:00 PM
Doyle Janeen NoelChief Corp. & Bus. Dev. OfcrJun 02 '26Sale14.034,05956,94475,941Jun 04 08:00 PM
Janeen Noel DoyleOfficerJun 02 '26Proposed Sale14.034,05956,944Jun 02 06:03 PM
Dobek MariaVice President, AccountingMay 11 '26Sale14.172,03828,87832,270May 13 08:00 PM
ANDY MEYERFormer AffiliateApr 13 '26Proposed Sale15.051,87728,246Apr 13 04:05 PM
ZACHARIAH A MCIVERFormer OfficerApr 02 '26Proposed Sale14.6574,8021,095,761Apr 02 04:02 PM
ANDY MEYERFormer AffiliateJan 26 '26Proposed Sale14.55178,7672,601,113Jan 26 04:20 PM
ANDY MEYERFormer AffiliateJan 23 '26Proposed Sale14.72118,1221,738,390Jan 23 04:08 PM
Meyer Andrew HollmanChief Business OfficerJan 02 '26Sale13.731,87925,79983,095Jan 02 09:00 PM
DiRaimondo ThomasChief Scientific OfficerJan 02 '26Sale13.732,50534,394124,425Jan 02 09:00 PM
Campbell David AlanPresident and CEOJan 02 '26Sale13.738,072110,829284,982Jan 02 09:00 PM
Winter Charles M.Chief Technical OfficerJan 02 '26Sale13.732,40132,96677,721Jan 02 09:00 PM
McIver ZachariahChief Medical OfficerJan 02 '26Sale13.732,71437,26323,286Jan 02 09:00 PM
Dobek MariaVice President, AccountingJan 02 '26Sale13.731,46220,07315,373Jan 02 09:00 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
FSCCFederated Hermes MDT Small Cap Core ETFAUM: 494.86M
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.340-0.474-0.3409.298.0318
2026Q22026-08-06-0.350-0.251-0.34910.2419.0717
2026Q12026-05-07-0.390-0.551-0.3893.744.3615
2025Q42026-02-26-0.510-0.625-0.5140.080.0814
2025Q32025-11-06-0.390-0.613-0.39210.002.8716
2025Q22025-08-07-0.550-0.472-0.5470.000.2711
2025Q12025-05-08-0.380-0.382-0.3800.000.5910
2024Q42025-02-27-0.360-0.461-0.3560.000.4113
2024Q32024-11-06-0.510-0.327-0.5140.441.5011
2024Q22024-08-07-0.110-0.311-0.1098.900.779
2024Q12024-05-07-0.300-0.331-0.3011.250.888
2023Q42024-03-08-0.250-0.415-0.2522.460.756
2023Q32023-11-07-0.250-0.470-0.2532.520.855
2022Q42023-08-09-0.390-0.481-0.3862.850.815
2023Q22023-08-08-0.420-0.502-0.4191.060.885
2023Q12023-05-09-0.420-0.486-0.4182.050.675

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-1.390-1.248-0.7923.642.45
2022FY-1.520-1.645-1.5218.616.58
2023FY-1.320-1.523-1.3248.086.37
2024FY-1.280-1.461-1.28410.5910.99
2025FY-1.830-1.977-1.83010.0810.06
2026FY--1.647--27.92
2027FY--2.565--7.12
2028FY--3.145--9.61
2029FY--3.334--39.37
2030FY--2.384--131.72

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0916234.03-3.3016.54
2026Q4S2026-11-0616324.04-3.3016.54
2026Q4S2026-11-0515007.290.0043.80
2026Q4S2026-10-2115007.290.0043.80
2026Q4S2026-08-1615417.290.0043.80
2026Q4S2026-08-1016416.840.0043.80
2026Q4S2026-08-0715416.360.0043.80
2026Q4S2026-07-2614004.100.0044.40
2026Q4S2026-07-2214014.100.0044.40
2026Q4S2026-06-2314324.100.0044.40
2026Q4S2026-05-1213324.420.0044.40
2026Q4S2026-05-0813315.180.0044.40
2026Q4S2026-04-2813206.230.0035.00
2026Q4S2026-04-2712206.750.0035.00

Estimate history

EPS, annual-0.096-0.163-0.792-1.521-1.324-1.284-1.834-1.5938
Period2019202020212022202320242025TTM
EPS, quarterly-0.514-0.356-0.38-0.547-0.392-0.514-0.389-0.349-0.342
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual003.6378.6128.08310.5881023.29
Period2019202020212022202320242025TTM
Sales, quarterly0.4390001003.73310.2679.289
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual41.61241.61241.24341.61646.25259.06560.38461.174
Period2019202020212022202320242025MRQ
Shares, quarterly52.33759.06559.16859.29860.12460.38460.86561.07861.174
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue23.2910.0010.598.088.613.640.000.00
Cost of Goods Sold Incl. D&A1.862.032.061.960.840.110.010.01
Gross Profit21.437.978.536.137.773.52-0.01-0.01
Selling, General and Administrative Excl. Other160.99165.64107.3879.1174.8636.454.833.77
Research and Development119.92125.9068.3954.9253.4426.243.043.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-139.56-157.67-98.85-72.98-67.09-32.93-4.84-3.77
Interest Expense0.000.000.000.000.000.000.210.23
Unusual Expense0.000.000.000.000.000.001.740.00
Net Income Before Taxes-99.85-113.62-68.99-58.29-63.06-32.67-6.78-4.00
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-99.85-113.62-68.99-58.29-63.06-32.67-6.78-4.00
Net Income From Continuing Operations-99.85-113.62-68.99-58.29-63.06-32.67-6.78-4.00
Net Income-99.85-113.62-68.99-58.29-63.06-32.67-6.78-4.00
EPS (Recurring)-1.58-1.83-1.28-1.32-1.52-0.79-0.13-0.10
EPS (Basic, Before Extraordinaries)-1.59-1.83-1.28-1.32-1.52-0.79-0.16-0.10
EPS (Diluted)-1.59-1.83-1.28-1.32-1.52-0.79-0.16-0.10
EBITDA-137.70-155.64-96.79-71.02-66.25-32.82-4.83-3.77
Non-Operating Income (Expense)39.7144.0429.8514.694.030.260.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense36.3840.2233.0220.000.631.930.070.01
Price To Sales Ratio46.8185.51271.8058.4363.42223.74--
Gross Margin92.0279.7180.5475.8190.2396.89--
Operating Margin-599.26-1,576.67-933.58-902.87-779.04-905.39--
Net Margin-428.74-1,136.25-651.62-721.18-732.22-898.32--
Shares Outstanding61.1760.3859.0646.2541.6241.2441.6141.61
Market Capitalization758.06758.063,094.59495.39548.70820.99827.65-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue9.2910.273.730.0010.000.000.000.00
Cost of Goods Sold Incl. D&A0.460.460.470.470.500.540.520.51
Gross Profit8.839.803.26-0.479.50-0.54-0.52-0.51
Selling, General and Administrative Excl. Other40.0941.4937.4841.9344.7544.5834.3828.51
Research and Development30.5730.9926.8131.5534.6334.6625.0520.81
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-31.26-31.69-34.21-42.40-35.25-45.12-34.90-29.02
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-21.57-21.97-24.36-31.95-24.31-33.86-23.51-20.22
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-21.57-21.97-24.36-31.95-24.31-33.86-23.51-20.22
Net Income From Continuing Operations-21.57-21.97-24.36-31.95-24.31-33.86-23.51-20.22
Net Income-21.57-21.97-24.36-31.95-24.31-33.86-23.51-20.22
EPS (Recurring)-0.34-0.35-0.39-0.51-0.39-0.55-0.38-0.36
EPS (Basic, Before Extraordinaries)-0.34-0.35-0.39-0.51-0.39-0.55-0.38-0.36
EPS (Diluted)-0.34-0.35-0.39-0.51-0.39-0.55-0.38-0.36
EBITDA-30.80-31.23-33.74-41.93-34.75-44.58-34.38-28.51
Non-Operating Income (Expense)9.699.729.8510.4610.9411.2611.398.81
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.549.069.279.529.0410.9610.706.25
Price To Sales Ratio46.8140.2863.4385.76151.593,257.28178.70287.38
Gross Margin95.0795.4987.44-94.99---
Operating Margin-336.51-308.66-916.50--352.51---
Net Margin-232.21-214.01-652.59--243.13---
Shares Outstanding61.1761.0860.8760.3860.1259.3059.1759.06
Market Capitalization758.06936.72845.56830.041,468.691,366.951,595.843,094.59

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments966.571,025.17344.03327.02374.967.810.66
Short Term Receivables6.4310.782.200.700.208.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets2.89-2.293.014.721.850.250.00
Total Current Assets975.891,033.67349.24332.44377.0216.060.66
Net Property, Plant & Equipment22.2524.1527.8429.361.600.150.02
Total Investments and Advances0.820.820.820.820.820.000.00
Intangible Assets-----0.000.00
Deferred Tax Assets5.96------
Other Assets2.612.882.511.390.390.000.00
Total Assets1,007.521,061.52380.41364.01379.8216.220.68
Short Term Debt Incl. Current Port. of LT Debt2.391.751.520.760.190.004.00
Accounts Payable4.974.032.422.162.460.430.27
Other Current Liabilities17.6311.689.0913.5910.142.750.36
Total Current Liabilities25.0017.4613.0316.5112.803.184.63
Long Term Debt19.7521.2823.0224.540.000.004.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities5.96------
Other Liabilities0.000.000.002.220.706.050.00
Total Liabilities50.7038.7336.0643.2713.509.238.62
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.0021.620.00
Common Equity956.821,022.78344.35320.74366.33-14.64-7.94
Total Shareholders Equity956.821,022.78344.35320.74366.336.99-7.94
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity956.821,022.78344.35320.74366.336.99-7.94
Total Liabilities & Stockholders Equity1,007.521,061.52380.41364.01379.8216.220.68
Book Value Per Share15.8517.327.447.718.88-0.35-0.19
Tangible Book Value Per Share15.8517.327.447.718.88-0.35-0.19
Full-Time Employees1098164603320-
Price to Book Ratio0.834.271.421.652.222.17-
Return on Assets-10.98-9.57-15.66-16.96-16.50-80.30-
Return on Equity-11.48-10.09-17.53-18.36-17.50--
Return on Invested Capital-11.64-6.61-15.87-18.26-8.92-97.11-
Quick Ratio39.0459.2126.8020.1429.465.050.14
Current Ratio39.0459.2126.8020.1429.465.050.14

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-99.85-113.62-68.99-58.29-63.06-32.67-6.78-4.00
Depreciation1.862.032.061.960.840.110.010.01
Other Funds (Non Cash)24.0222.6522.4312.3215.026.742.010.24
Funds from Operations-73.97-88.95-44.50-44.02-47.20-25.82-4.76-3.76
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital20.396.710.69-6.554.288.840.39-0.07
Cash from Operating Activities-53.58-82.23-43.81-50.58-42.92-16.98-4.37-3.83
Capital Expenditures-0.58-1.04-0.36-1.85-6.45-1.480.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments38.01-299.94-257.66-39.3464.71-339.480.000.00
Purchase of Investments-457.37-705.22-470.58-317.34-294.39-473.630.000.00
Sale Or Maturity of Investments495.38405.28212.91278.00359.10134.150.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities37.42-300.98-258.02-41.1958.27-340.960.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock9.584.95713.2459.550.50386.529.020.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock9.584.95713.2459.550.50386.529.020.00
Proceedsfrom Stock Options0.000.00698.2756.530.00384.718.950.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.002.504.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities9.584.95713.2459.550.50386.5211.524.00
Net Change in Cash-6.57-378.27411.40-32.2215.8428.597.160.17
Free Cash Flow-54.16-83.28-44.17-52.42-49.37-18.46-4.37-3.83
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments945.72970.91956.39966.57988.99996.01
Short Term Receivables6.616.3342.466.436.325.69
Inventories0.000.000.000.000.000.00
Other Current Assets7.056.103.202.892.783.85
Total Current Assets959.38983.341,002.05975.89998.091,005.55
Net Property, Plant & Equipment19.5720.5921.4222.2523.2423.15
Total Investments and Advances0.820.820.820.820.820.82
Deferred Tax Assets---5.96--
Other Assets3.892.913.942.612.632.69
Total Assets983.651,007.651,028.221,007.521,024.771,032.21
Short Term Debt Incl. Current Port. of LT Debt2.632.552.472.392.281.87
Accounts Payable4.303.023.384.973.403.48
Other Current Liabilities47.3154.5853.0717.6322.1616.03
Total Current Liabilities54.2560.1558.9125.0027.8321.38
Long Term Debt17.7518.4419.1019.7520.3820.32
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---5.96--
Other Liabilities0.051.088.680.000.000.00
Total Liabilities72.0479.6786.6950.7048.2141.70
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity911.61927.98941.53956.82976.55990.52
Total Shareholders Equity911.61927.98941.53956.82976.55990.52
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity911.61927.98941.53956.82976.55990.52
Total Liabilities & Stockholders Equity983.651,007.651,028.221,007.521,024.771,032.21
Book Value Per Share14.9015.1915.4715.8516.2416.70
Tangible Book Value Per Share14.9015.1915.4715.8516.2416.70
Full-Time Employees114--109-103
Price to Book Ratio0.830.990.880.851.461.35
Return on Assets-9.94-10.06-11.01-10.98-11.85-12.26
Return on Equity-10.58-10.70-11.72-11.48-12.48-12.82
Return on Invested Capital-2.32-2.32-2.54-3.27-2.44-3.35
Quick Ratio17.6916.3517.0139.0435.8647.03
Current Ratio17.6916.3517.0139.0435.8647.03

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-21.57-21.97-24.36-31.95-24.31-33.86
Depreciation0.460.460.470.470.500.54
Other Funds (Non Cash)5.216.186.645.994.425.75
Funds from Operations-15.90-15.33-17.25-25.49-19.39-27.56
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-9.2827.824.91-3.066.543.75
Cash from Operating Activities-25.1812.48-12.34-28.54-12.86-23.81
Capital Expenditures-0.00-0.20-0.27-0.11-0.09-0.47
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments38.38-38.588.5629.658.402.04
Purchase of Investments-76.50-144.84-112.75-123.28-117.97-92.69
Sale Or Maturity of Investments114.88106.26121.31152.93126.3794.72
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities38.38-38.788.2929.548.311.56
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.852.243.542.940.490.95
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.852.243.542.940.490.95
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.852.243.542.940.490.95
Net Change in Cash14.05-24.06-0.513.94-4.06-21.30
Free Cash Flow-25.1812.28-12.61-28.65-12.95-24.29

Revenue breakdown

Pharmaceutical Preparations2024: 10.59M 2025: 10.00M
United States2024: 10.59M 2025: 10.00M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.21%5.3M57.9M821.84K
2026-10-159.21%5.3M57.8M841.09K
2026-09-309.83%5.7M57.8M863.30K
2026-09-1510.19%5.9M57.8M1.02M
2026-08-3110.49%6.1M57.8M969.78K
2026-08-1411.46%6.6M57.8M1.03M
2026-07-3110.33%5.9M57.4M1.06M
2026-07-1511.30%6.5M57.1M1.12M
2026-06-3012.41%7.1M57.3M1.11M
2026-06-1513.30%7.6M57.3M1.02M
2026-05-2914.14%8.1M57.2M1.05M
2026-05-1513.75%7.8M56.9M1.00M
2026-04-3014.23%7.9M55.7M1.10M
2026-04-1514.16%7.4M52.6M1.24M
2026-03-3114.74%7.7M52.6M1.33M
2026-03-1319.07%10.0M52.6M1.57M
2026-02-2719.02%10.0M52.6M2.06M
2026-02-1319.52%10.1M52.0M2.11M
2026-01-3019.61%10.5M53.4M2.05M
2026-01-1517.66%9.4M53.5M1.92M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.507.8011.900.0021.4400.000.000.976-0.0450.001
call5.005.309.400.0010.6540.000.000.955-0.0450.002
call7.502.956.900.006.9050.000.000.925-0.0410.003
call9.001.455.400.005.3760.000.000.896-0.0370.003
call10.000.354.400.004.5000.000.000.866-0.0340.004
call11.000.003.500.003.8410.000.000.739-0.0530.006
call12.500.001.150.651.55632.005.000.524-0.0570.008
call14.000.002.350.102.2613.000.000.433-0.0970.008
call15.000.000.250.201.08644.001.000.149-0.0280.004
call16.000.002.150.001.5450.000.000.174-0.0430.005
call17.500.002.150.051.8778470.000.151-0.0480.005
call19.000.002.151.102.16515.000.000.136-0.0520.004
call20.000.000.100.041.8884,5215.000.069-0.0280.003
call21.000.002.150.002.0310.000.000.066-0.0280.002
call22.500.002.000.102.2271030.000.061-0.0290.002
call24.000.002.150.002.4080.000.000.058-0.0300.002
call25.000.002.150.012.5201111.000.056-0.0310.002
call26.000.002.150.002.6260.000.000.054-0.0310.002
call27.000.002.150.002.7270.000.000.052-0.0320.002
call28.000.002.150.002.8240.000.000.051-0.0320.002
call29.000.002.150.002.9160.000.000.050-0.0330.002
call30.000.001.000.052.9322890.000.049-0.0330.002
call31.000.002.150.003.0890.000.000.048-0.0340.002
call32.000.002.150.003.1700.000.000.047-0.0340.002
put2.500.002.150.007.2810.000.00-0.024-0.0450.001
put5.000.002.150.004.2810.000.00-0.045-0.0440.002
put7.500.002.150.002.6110.000.00-0.075-0.0400.003
put9.000.002.150.001.8460.000.00-0.104-0.0360.003
put10.000.000.200.111.1945.000.00-0.121-0.0250.004
put11.000.000.750.411.46015.000.00-0.261-0.0510.006
put12.500.000.800.750.9731,152212-0.476-0.0550.008
put14.000.003.900.003.5050.000.00-0.567-0.0960.008
put15.000.553.703.102.5662610.00-0.802-0.0380.005
put16.001.555.700.004.2100.000.00-0.826-0.0420.005
put17.503.007.102.224.5081,1090.00-0.849-0.0460.005
put19.004.608.600.004.8770.000.00-0.864-0.0500.004
put20.005.509.603.405.09822.000.00-0.931-0.0250.003
put21.006.5010.600.005.3020.000.00-0.934-0.0260.002
put22.508.0012.100.005.5830.000.00-0.939-0.0270.002
put24.009.5013.600.005.8360.000.00-0.942-0.0280.002
put25.0010.5014.600.005.9930.000.00-0.944-0.0280.002
put26.0011.5015.600.006.1410.000.00-0.946-0.0290.002
put27.0012.5016.600.006.2820.000.00-0.948-0.0290.002
put28.0013.5017.600.006.4150.000.00-0.949-0.0290.002
put29.0014.5018.600.006.5420.000.00-0.950-0.0300.002
put30.0015.5019.600.006.6640.000.00-0.951-0.0300.002
put31.0016.5020.700.006.7790.000.00-0.952-0.0300.002
put32.0017.5021.600.006.8900.000.00-0.953-0.0300.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-314Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-07-28SCHEDULE 13G/ASEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-06-238-KCurrent report2026-06-23SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-128-KCurrent report2026-06-11SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-02SEC
2026-06-02144Filing for proposed sale of securities under Rule 144.SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-12SCHEDULE 13GSEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-05-06SCHEDULE 13G/ASEC
2026-04-29SCHEDULE 13GSEC
2026-04-29SCHEDULE 13GSEC
2026-04-288-KCurrent report2026-04-28SEC
2026-04-28ARSAnnual report to security holders. 2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060056.94K1
2026-050028.88K1
2026-040000
2026-030000
2026-020000
2026-0100261.32K6
2025-1200109.93K1
2025-110099.99K1

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.18.35%
BlackRock, Inc.10.06%
Prosight Management, LP6.24%
STATE STREET CORP4.93%
FMR LLC4.11%
FEDERATED HERMES, INC.3.86%
Point72 Asset Management, L.P.3.27%
VANGUARD CAPITAL MANAGEMENT LLC3.05%
TCG Crossover Management, LLC2.93%
Alyeska Investment Group, L.P.2.70%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.16%
Federated Hermes MDT Small Cap Core Fund2.25%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.07%
iShares Russell 2000 ETF1.85%
VANGUARD EXTENDED MARKET INDEX FUND0.91%
Fidelity Small Cap Index Fund0.77%
VANGUARD STRATEGIC EQUITY FUND0.69%
iShares Russell 2000 Value ETF0.66%
iShares Biotechnology ETF0.66%
Nuveen Quant Small Cap Equity Fund0.62%

OakChart. JANX. Cached 15 minutes.